Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 146 publications
Phase I first-in-human dose-escalation trial of a bladder cancer-specific nanoparticle in non-muscle-invasive bladder cancer.
Journal: Nanomedicine (London, England)
Published: July 08, 2026
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/Docetaxel.
Journal: bioRxiv : the preprint server for biology
Published: June 04, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 15, 2026
Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC).
Journal: Clinical genitourinary cancer
Published: April 12, 2026
Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.
Journal: medRxiv : the preprint server for health sciences
Published: April 03, 2026
Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: January 16, 2026
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 03, 2025
ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 07, 2025
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.
Journal: Future oncology (London, England)
Published: April 01, 2025
A pilot study of [18F]F-fluciclovine positron emission tomography/computed tomography for staging muscle invasive bladder cancer preceding radical cystectomy.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 08, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial.
Journal: The Lancet. Oncology
Published: February 05, 2025
Last Updated: 09/26/2026